This company listing is no longer active
Gracell Biotechnologies Balance Sheet Health
Financial Health criteria checks 5/6
Gracell Biotechnologies has a total shareholder equity of CN¥1.6B and total debt of CN¥103.1M, which brings its debt-to-equity ratio to 6.4%. Its total assets and total liabilities are CN¥1.9B and CN¥268.9M respectively.
Key information
6.36%
Debt to equity ratio
CN¥103.15m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥1.71b |
| Equity | CN¥1.62b |
| Total liabilities | CN¥268.86m |
| Total assets | CN¥1.89b |
Recent financial health updates
Recent updates
AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)
Feb 21Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform
Sep 22Gracell Biotechnologies GAAP EPS of -$0.06 beats by $0.02
Aug 15Gracell Biotechnologies rallies after naming new chief medical officer
Aug 01Gracell names Dr. Samuel Zhang as Chief Business Officer
Jul 19Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment
Nov 26Financial Position Analysis
Short Term Liabilities: GRCL's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥229.5M).
Long Term Liabilities: GRCL's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥39.4M).
Debt to Equity History and Analysis
Debt Level: GRCL has more cash than its total debt.
Reducing Debt: Insufficient data to determine if GRCL's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GRCL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GRCL has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 33.3% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/21 05:44 |
| End of Day Share Price | 2024/02/21 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gracell Biotechnologies Inc. is covered by 8 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Louise Chen | Cantor Fitzgerald & Co. |
| Yigal Nochomovitz | Citigroup Inc |